Clinical trial
Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral…
NCT00159731 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159731 |
|---|---|
| Title | Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy |
| Official title | An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Peripheral Neuropathy |
| Intervention type | Drug |
| Interventions | Pregabalin |
| Enrollment | 160 |
| Start date | Jan 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 22, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: